We are live on ! Find out more
CSCI

COSCIENS Biopharma Inc. Common Stock

Delisted

CSCI was delisted on the 3rd of September, 2025.

10 hedge funds and large institutions have $1.24M invested in COSCIENS Biopharma Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

41% less funds holding

Funds holding: 1710 (-7)

78% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 9

86% less capital invested

Capital invested by funds: $8.97M → $1.24M (-$7.73M)

Holders
10
Holders Change
-7
Holders Change %
-41.18%
% of All Funds
0.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
2
Reduced
3
Closed
9
Calls
Puts
Net Calls
Net Calls Change

CSCI Hedge Fund Activity: Q2 2015 in Review

10 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2015, worth a combined $1.24M — down 86% from $8.97M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of CSCI and 2 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $1.1M. The largest seller was Susquehanna International Group, cutting an estimated $3.43M.

  • 10 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2015, down from 17 in Q1 2015.
  • Funds reported $1.24M of COSCIENS Biopharma Inc. Common Stock stock for Q2 2015, down 86% quarter-over-quarter.
  • 2 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2015 and 9 closed out, a net change of -7 holders.
  • The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2015 was Renaissance Technologies, an estimated $1.1M added.
  • The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2015 was Susquehanna International Group, an estimated $3.43M sold.

Based on aggregated 13F filings for Q2 2015.